QR Pharma, Inc is a specialty pharmaceutical company founded to develop novel drugs for the treatment of Alzheimer’s Disease (AD). The company has two compounds in clinical development. Posiphen and Bisnorcymserine (BNC) work by two novel, different, and independent mechanisms of action.The lead compound, Posiphen, has the potential to be disease modifying and stop the progression of the disease.Its distinct and different mechanism of action makes Posiphen better suited for mild cognitive impairment (MCI) and early AD. The second compound, BNC, inhibits butyrylcholinesterase and has symptomatic efficacy. Due to their interesting mechanisms of action, the company is targeting Posiphen for MCI and early AD and BNC for moderate to late AD.
OR Pharma previously presented at OneMedForum San Francisco and will return in June to present their technology at OneMedForum NY 2011. Read More